WO1999051735A2 - Mapkap kinase 2-hemmer und ihre verwendung für die anti-inflammatorische therapie - Google Patents
Mapkap kinase 2-hemmer und ihre verwendung für die anti-inflammatorische therapie Download PDFInfo
- Publication number
- WO1999051735A2 WO1999051735A2 PCT/DE1999/000990 DE9900990W WO9951735A2 WO 1999051735 A2 WO1999051735 A2 WO 1999051735A2 DE 9900990 W DE9900990 W DE 9900990W WO 9951735 A2 WO9951735 A2 WO 9951735A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mapkap kinase
- inhibitors
- kinase
- mapkap
- inflammatory
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 12
- 238000011861 anti-inflammatory therapy Methods 0.000 title abstract description 5
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 claims abstract description 25
- 108010041955 MAP-kinase-activated kinase 2 Proteins 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 6
- 230000030570 cellular localization Effects 0.000 claims abstract description 4
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 4
- 239000000126 substance Substances 0.000 claims description 5
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 3
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 3
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 3
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- XEIVCDDCSGGZSG-UHFFFAOYSA-N 7-[3-[(3-formylphenoxy)methyl]-1,5-dimethylpyrazol-4-yl]-3-(3-naphthalen-1-yloxypropyl)-1H-indole-2-carboxylic acid Chemical compound Cc1c(c(COc2cccc(C=O)c2)nn1C)-c1cccc2c(CCCOc3cccc4ccccc34)c([nH]c12)C(O)=O XEIVCDDCSGGZSG-UHFFFAOYSA-N 0.000 claims 1
- 101150036080 at gene Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000028709 inflammatory response Effects 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 5
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 5
- 206010040070 Septic Shock Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000036303 septic shock Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- NSEDOQSDUNWXQE-UHFFFAOYSA-N 4-[2-(4-methylsulfinylphenyl)-1h-imidazol-5-yl]pyridine Chemical compound C1=CC(S(=O)C)=CC=C1C1=NC=C(C=2C=CN=CC=2)N1 NSEDOQSDUNWXQE-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 108010084680 Heterogeneous-Nuclear Ribonucleoprotein K Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- MAPKAP Kinase 2 inhibitors and their use for anti-inflammatory therapy
- the invention relates to MAPKAP kinase 2 inhibitors and their use for anti-inflammatory therapy. Areas of application of the invention are medicine and the pharmaceutical industry.
- the majority of all diseases are associated with inflammatory processes, which lead to the cause of the disease being identified and eliminated.
- the early inflammatory response e.g. in response to bacterial lipopolysaccharides (LPS)
- LPS bacterial lipopolysaccharides
- TNF ⁇ tumor necrosis factor ⁇
- 11-1 interleukin-1
- SB203580 can effectively inhibit the inflammatory response in response to LPS administration and at the same time inhibit the biosynthesis of 11-1 and TNF ⁇ .
- the mechanism of stimulation of the cytokine biosynthesis by the p38 MAP kinase has so far only been incompletely understood.
- Substrates of the p38 MAP kinase have been considered different transcription factors and protein kinases were identified. These doinstream components of signaling by p38 MAPK could be involved individually or together in the inflammatory response.
- the invention is therefore based on the object of providing, on the basis of a new active principle, agents which can be used as anti-inflammatory therapeutic agents with as few side effects as possible.
- MAPKAP Kinase 2 is the ideal target for anti-inflammatory therapy to use.
- the invention is characterized in that the action of MAPKAP kinase 2 is specifically inhibited. According to the invention, this can be done in three different ways.
- oligonucleotides which are suitable for specifically inhibiting the expression of MAPKAP kinase 2 in human cells.
- Suitable oligonucleotides include
- the invention enables a targeted therapy of the inflammatory response and can therefore be of fundamental importance for modern medicine.
- a MAPKAP K2 knock out mouse was generated using the gene targeting method. This mouse is viable, shows no pathological changes to tissues and organs, as far as examined so far, but a significantly reduced LPS-induced inflammatory response. This is shown, for example, by a significantly increased survival of the knock-out mice in septic shock ( Figure 1). Furthermore, the serum concentrations of TNF ⁇ 90 min after LPS stimulation in the knock outs are more than 10 times lower than the concentrations in comparable wild animals (see table). These data clearly demonstrate that MAPKAP Kinase 2 plays an essential role in the inflammatory response and is not necessary for normal mouse development. Table: Serum concentration of TNF ⁇ in MAPKAP kinase 2 knock outs and wild type 90 min after injection ip of 1 ⁇ g LPS
- MAPKAP Kinase 2 knock out mice in septic shock caused by injection of 2 ⁇ g LPS / 20 mg galactosamine. While the control animals completely succumb to septic shock after 11 hours, the knock-out animals show a significantly increased survival due to a reduced inflammatory response.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/647,701 US6683172B1 (en) | 1998-04-03 | 1999-04-01 | Mapkap kinase 2-inhibitors and the use thereof in anti-inflammatory therapy |
EP99924743A EP1108016A2 (de) | 1998-04-03 | 1999-04-01 | Mapkap kinase 2-hemmer und ihre verwendung für die anti-inflammatorische therapie |
JP2000542448A JP2002510714A (ja) | 1998-04-03 | 1999-04-01 | Mapkapキナーゼ−2阻害剤および抗炎症治療におけるその使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19814963A DE19814963A1 (de) | 1998-04-03 | 1998-04-03 | MAPKAP Kinase 2-Hemmer und ihre Verwendung für die anti-inflammatorische Therapie |
DE19814963.8 | 1998-04-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999051735A2 true WO1999051735A2 (de) | 1999-10-14 |
WO1999051735A3 WO1999051735A3 (de) | 2001-04-12 |
Family
ID=7863483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1999/000990 WO1999051735A2 (de) | 1998-04-03 | 1999-04-01 | Mapkap kinase 2-hemmer und ihre verwendung für die anti-inflammatorische therapie |
Country Status (5)
Country | Link |
---|---|
US (1) | US6683172B1 (de) |
EP (1) | EP1108016A2 (de) |
JP (1) | JP2002510714A (de) |
DE (1) | DE19814963A1 (de) |
WO (1) | WO1999051735A2 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6909001B2 (en) | 2002-12-12 | 2005-06-21 | Pharmacia Corporation | Method of making tricyclic aminocyanopyridine compounds |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8440610B2 (en) | 2004-11-12 | 2013-05-14 | Massachusetts Institute Of Technology | Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells |
EP1824498A4 (de) * | 2004-11-12 | 2009-06-24 | Massachusetts Inst Technology | Verfahren und zusammensetzungen zur behandlung proliferativer zellkrankheiten |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997034137A2 (en) * | 1996-03-12 | 1997-09-18 | Smithkline Beecham Corporation | Methods of the identification of pharmaceutically active compounds |
-
1998
- 1998-04-03 DE DE19814963A patent/DE19814963A1/de not_active Withdrawn
-
1999
- 1999-04-01 EP EP99924743A patent/EP1108016A2/de not_active Withdrawn
- 1999-04-01 WO PCT/DE1999/000990 patent/WO1999051735A2/de active Application Filing
- 1999-04-01 US US09/647,701 patent/US6683172B1/en not_active Expired - Fee Related
- 1999-04-01 JP JP2000542448A patent/JP2002510714A/ja not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997034137A2 (en) * | 1996-03-12 | 1997-09-18 | Smithkline Beecham Corporation | Methods of the identification of pharmaceutically active compounds |
Non-Patent Citations (6)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6909001B2 (en) | 2002-12-12 | 2005-06-21 | Pharmacia Corporation | Method of making tricyclic aminocyanopyridine compounds |
Also Published As
Publication number | Publication date |
---|---|
JP2002510714A (ja) | 2002-04-09 |
EP1108016A2 (de) | 2001-06-20 |
US6683172B1 (en) | 2004-01-27 |
DE19814963A1 (de) | 1999-10-07 |
WO1999051735A3 (de) | 2001-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pauly et al. | Chronic nicotine and mecamylamine treatment increase brain nicotinic receptor binding without changing alpha 4 or beta 2 mRNA levels. | |
Kleim et al. | Motor learning-dependent synaptogenesis is localized to functionally reorganized motor cortex | |
Bédard et al. | The nigrostriatal pathway: A correlative study based on neuroanatomical and neurochemical criteria in the cat and the monkey | |
Meyn et al. | Induction of apoptosis in murine tumors by cyclophosphamide | |
DE69433309T2 (de) | Verbeugende oder therapeutische Mittel für die Alzheimer-Krankheit, eine Siebtest-Methode, und die menschliche Tau-Protein-Kinase | |
WO2002018407A9 (de) | Antisense oligonukleotide gegen vanilloid rezeptor 1 | |
DE19917990A1 (de) | Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk | |
Anjos et al. | Poisoning of sheep by seeds of Crotalaria retusa: Acquired resistance by continuous administration of low doses | |
Battista et al. | Mapping of central monoamine neurons in the monkey | |
AU6466096A (en) | Therapeutic use of d-threo-methylphenidate | |
DE69831950T2 (de) | Inhibitoren des hitzeschock-faktors | |
Morency et al. | Circling behavior following unilateral microinjections of cocaine into the medial prefrontal cortex: dopaminergic or local anesthetic effect? | |
WO2004060360A1 (de) | Verwendung von wirksubstanzen zur prophylaxe und/oder therapie von viruserkrankungen | |
WO1999051735A2 (de) | Mapkap kinase 2-hemmer und ihre verwendung für die anti-inflammatorische therapie | |
WO2003106681A2 (de) | Antisense oligonukleotide gegen pim1 | |
DE60026347T2 (de) | Anwendung von nicht menschliches SHIP2 'Knock-out' Säugtiere | |
DE69927987T2 (de) | Hemmung von mit gewebetrauma verbundenen pathogenen prozessen | |
DE102013110608A1 (de) | Substanz zur Hemmung von Gewebskalzifizierung, Gewebsfibrosierung und altersassoziierten Erkrankungen | |
US6087377A (en) | Tamoxifen as a therapy to reduce irinotecan hydrochloride-induced diarrhea | |
WO2002066027A1 (de) | Mittel zur hemmung von tumorzellen | |
DE69724447T2 (de) | Verfahren zur identifizierung von pharmazeutika aus pflanzenextrakten | |
Feldman et al. | Single-cell and multiunit activity in freely moving rats after corticosterone administration | |
DE10211558A1 (de) | Neue Formen RNAi | |
DE1617950A1 (de) | Verfahren zur Beeinflussung der Immunitaet oder Widerstandskraft eines Wirtsorganismus | |
WO2024003227A1 (de) | Artifizielles peptid mit pkmt-inhibitorischer wirkung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999924743 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09647701 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWP | Wipo information: published in national office |
Ref document number: 1999924743 Country of ref document: EP |